Medicine & Health

The asynchronous progression of stria vascularis (SV) atrophy and spiral ganglion neuron (SGN) loss is the central puzzle in presbycusis. Current models treat these as parallel degenerations sharing root causes (oxidative stress, inflammation), but fail to explain why SGN loss often accelerates after significant SV decline. Here I propose a causal priming mechanism: early, localized aldosterone deficiency in the cochlear lateral wall directly reduces NKCC1 expression and endocochlear potential (EP), creating a chronic, mild metabolic stress in the SGN somata housed in Rosenthal's canal. This stress doesn't kill neurons but primes them by chronically upregulating activity of T-type CaV3.2 calcium channels as a compensatory attempt to maintain excitability. The neuron's calcium handling system is thus pushed toward a higher baseline, leaving it hypersensitive to any secondary insult—glutamate excitotoxicity, age-related increases in ambient glutamate, or stochastic inflammatory signals. This two-hit model explains the temporal disconnect: SV decline (Hit 1) establishes a vulnerable metabolic niche, while later-life triggers (Hit 2) rapidly deplete the compromised SGN population.

Novel mechanistic reasoning beyond the literature: The aldosterone-SGN survival link [https://www.aging-us.com/article/101045/text] is currently framed as a direct neuroprotective effect. I propose its primary role is indirect, via SV-mediated metabolic priming. The preserved SGNs seen with CaV3.2 blockade [https://pubmed.ncbi.nlm.nih.gov/21640179/] support this—the drug isn't just

The civilization-versus-survival dial metaphor for mTOR activity assumes a systemic tradeoff: global anabolism versus global maintenance. Yet evidence suggests tissue-specific needs. Neurons require constant autophagy for proteostasis, while intestinal stem cells demand high mTOR for rapid renewal. Hypothesis: Longevity optimization depends not on systemic mTOR suppression, but on maintaining tissue-specific mTOR activity gradients that are disrupted during aging.

Proposed Mechanism

• Calibration via nutrient-sensing heterogeneity: Different tissues express varying levels of AMPK, sirtuins, and REDD1, creating intrinsic mTOR sensitivity gradients [pmc.ncbi.nlm.nih.gov/articles/PMC6611156]. For example, high SIRT1 in neurons may suppress mTORC1 locally even during fed states.
• Aging disrupts gradients: Systemic inflammation and mitochondrial dysfunction [pmc.ncbi.nlm.nih.gov/articles/PMC7253058] may blunt AMPK signaling in some tissues (e.g., muscle) while hyperactivating mTOR in others (e.g., adipose), leading to inappropriate anabolism in post-mitotic tissues and impaired regeneration in stem cell niches.
• Centenarian variants may preserve gradients: Rare mTOR pathway variants in centenarians [www.nad.com/news/the-secret-to-a-long-life-may-be-hidden-in-the-mtor-pathway-german-scientists-find] might not globally inhibit mTOR, but rather maintain youthful tissue-specific patterns.

Testable Predictions

1. Tissue-specific mTOR activity mapping in aging mice will show loss of gradient homogeneity (e.g., elevated mTOR in brain, suppressed in gut s

Background

Patients with systemic lupus erythematosus (SLE) exhibit accelerated atherosclerosis and coronary microvascular dysfunction (CMD) disproportionate to traditional cardiovascular risk factors. Glycemic variability (GV), measurable via continuous glucose monitoring (CGM), reflects endothelial oxidative stress burden through recurrent glucose excursions that activate NADPH oxidase and suppress endothelial nitric oxide synthase. We hypothesize that CGM-derived GV indices — specifically coefficient of variation (%CV), mean amplitude of glycemic excursions (MAGE), and time-in-range (TIR) — capture subclinical endothelial injury in SLE patients and predict CMD progression 6–18 months before functional imaging detection.

Hypothesis

In non-diabetic SLE patients, a composite CGM-derived glycemic variability score (integrating %CV >36%, MAGE >3.0 mmol/L, and TIR <70%) measured over 14-day monitoring periods predicts coronary microvascular dysfunction — defined by coronary flow reserve (CFR) <2.5 on stress echocardiography — with >75% sensitivity and >70% specificity, 6–18 months before CFR deterioration becomes detectable.

Mechanism

Recurrent glycemic excursions → peroxynitrite-mediated endothelial glycocalyx degradation → reduced shear-stress mechanotransduction → impaired flow-mediated coronary dilation. In SLE, this pathway is amplified by: (1) type I interferon-driven endothelial progenitor cell exhaustion, (2) anti-endothelial cell antibody-mediated complement activation on microvasculature, and (3) immune complex deposition in coronary arterioles. The GV

Aging impairs tissue regeneration, and the Hedgehog (Hh) pathway is a known casualty. However, the prevailing model focuses on reduced amplitude—less pathway activation. This misses the point. A more fundamental flaw likely lies in corrupted temporal control. The Hh pathway isn't just a simple on/off switch; it's a dynamic timer.

Developmental neurobiology reveals that graded Gli activator (GliA) and repressor (GliR) concentrations arise from differential transcriptional decay rates, even under full SMO activation, creating a precise timing mechanism for fate decisions (Science Advances, 2020). This "GLI timer" has never been examined in aging, where its failure could explain multiple repair defects.

Hypothesis: Age-related fibroblast dysfunction in wound repair and angiogenesis is caused not merely by attenuated SMO signaling, but by disrupted kinetics of GliA/GliR decay. Aged cells exhibit prolonged GliA and/or GliR half-lives, flattening and extending the temporal gradient. This results in a temporally "stuck" signaling state that fails to execute timely transcriptional programs for mesenchymal-to-epithelial transition (JCI, 2012) and pro-angiogenic signaling, and may paradoxically promote fibrosis.

Mechanistic Rationale:

1. The Missing Switch: The acute-to-persistent SMO signaling paradox is likely resolved by the GliA/GliR ratio over time, not just SMO status. A persistent GliA signal without timely counter-regulation by GliR decay could lock cel

Background

Stochastic portfolio theory (SPT), developed by Fernholz (2002) for equity markets, provides a mathematical framework for analyzing the behavior of diverse portfolios under stochastic dynamics without requiring parametric assumptions about asset returns. We propose applying SPT concepts — particularly the excess growth rate generated by portfolio diversity — to the problem of multi-drug regimen optimization in systemic lupus erythematosus (SLE).

Hypothesis

We hypothesize that treating concurrent immunosuppressive agents as "assets" in a therapeutic portfolio, where each drug's efficacy trajectory follows a semimartingale process conditioned on patient-specific pharmacogenomic covariates (NAT2, CYP2C19, TPMT, UGT1A9), a diversity-weighted therapeutic portfolio — one that maintains sufficient heterogeneity across mechanistic pathways (complement inhibition, B-cell depletion, calcineurin inhibition, antimetabolites) — will generate an excess therapeutic return analogous to the excess growth rate in SPT, resulting in >20% greater cumulative SLEDAI reduction over 24 months compared to sequential monotherapy switching.

Mathematical Framework

Let $X_i(t)$ represent the efficacy process of drug $i$ at time $t$, modeled as:

$$dX_i(t) = X_i(t)[\gamma_i(\mathbf{G}) dt + \sigma_i(\mathbf{G}) dW_i(t)]$$

where $\gamma_i(\mathbf{G})$ is the pharmacogenomically-conditioned drift (expected efficacy rate) and $\sigma_i(\mathbf{G})$ captures stochastic variability dependent on genotype vector $\mathbf{G}$. The portfolio diversity measure $D(\boldsymbol{\mu}(

We usually talk about the glymphatic system as the brain's waste management, clearing out metabolic byproducts like Aβ and Tau. But we might be viewing "waste" too narrowly—it isn't just pathology, it's a functional part of our cognitive state. The circadian regulator BMAL1 acts as the master switch here, upregulating the fusion protein STX17 to drive autophagy [PMC11647228] and keeping the protein-synthesis driver mTORC1 in check [Aging-US 100633].

I don't see sleep as just a metabolic reset. It’s a specific proteostatic "narrowing" event. During wakefulness, our synapses produce a huge variety of proteins—like Arc, Fos, or specific CaMKII isoforms—based on what we're experiencing. If the BMAL1-STX17 clearance pathway fails, these proteins aren't fully recycled. They persist as a "Shadow Proteome." This molecular residue creates a kind of biological noise that makes it hard for the brain to encode new, coherent identity-forming experiences.

In people with chronic circadian misalignment, like shift workers, this leads to a state of "Proteostatic Inertia." Because they don't inhibit mTORC1 or activate STX17 properly, semi-stable synaptic scaffolds just pile up. This shadow proteome acts as a molecular anchor, tethering them to past emotional states and physically blocking the formation of new ones. It’s a literal erosion of self.

The mechanics involve what I call the mTORC1/STX17 scissors. In a healthy cycle, low nocturnal mTORC1 activity [Aging-US 100633] allows for protein turnover. But for shift workers, suppressed BMAL1 leads to hyperactive mTORC1, which keeps

Selective autophagy employs a dynamic hierarchy of receptors (p62, NBR1, OPTN, NDP52) whose dominance shifts based on metabolic state and stress type [1][2]. Recent evidence shows inflammation induces early upregulation of ER-phagy receptors (OPTN, SEC62), prioritizing ER turnover at the expense of other pathways [3]. I propose this stress-induced receptor reprioritization is a transient, adaptive program that becomes chronically locked during aging, leading to pathological organelle accumulation patterns rather than global autophagy failure.

The mechanistic core: Stress-specific signaling creates a transcriptional and post-translational "receptor imprint" that persists after stress resolution. Acute inflammation activates NF-κB and ATF4 pathways, which upregulate OPTN/SEC62 [3]. In young cells, resolution of inflammation allows mTORC1/AMPK rebalancing and receptor profile reset. In aging, cumulative stressors (chronic inflammation, ER stress, metabolic shifts) may create overlapping, persistent signaling that locks cells into a dominant ER-phagy program. This comes at the direct expense of mitophagy and pexophagy receptors, whose basal expression declines through competitive autophagy receptor network dynamics [1].

Testable prediction: Aged neurons or hepatocytes will show:

1. Persistently elevated OPTN/SEC62:ER-phagy flux ratios even after resolution of inflammatory stimuli
2. Correspondingly reduced p62/NBR1-mediated mitochondrial and peroxisomal clearance
3. This pattern will be reversed by transient OPTN knockdown followed by recovery period, not by globa

Background

Giant cell arteritis (GCA) relapse monitoring relies primarily on serial CRP and ESR measurements, which lack specificity and often lag behind vascular inflammation. Platelet-to-lymphocyte ratio (PLR) is an accessible inflammatory biomarker computable from routine complete blood counts, yet its static single-timepoint values have shown limited predictive utility.

Hypothesis

We hypothesize that the coefficient of variation (CV) and autocorrelation structure of serial PLR measurements — computed from ≥6 routine CBCs over rolling 12-week windows — captures subclinical oscillatory inflammatory dynamics in large-vessel vasculitis that precede clinical relapse. Specifically:

1. PLR variability index (CV of PLR over 12 weeks) >0.18 identifies patients in a pre-relapse inflammatory regime with >75% sensitivity and >70% specificity, 8–16 weeks before CRP exceeds 10 mg/L.
2. Loss of PLR autocorrelation (lag-1 autocorrelation dropping below 0.3) signals breakdown of homeostatic immune regulation and correlates with impending vascular wall inflammation detectable on PET-CT.
3. The combination of PLR-CV and PLR autocorrelation outperforms static CRP, ESR, and IL-6 thresholds (AUC >0.82 vs <0.68) for early relapse detection.

Rationale

Vascular inflammation in GCA involves cyclic platelet activation, megakaryocyte stimulation via IL-6/TPO, and lymphocyte redistribution to inflamed vessel walls. These dynamics create measurable oscillations in peripheral PLR that are invisible in single-timepoint analysis but emerge in time-series variability metrics.

Hypothesis: In a retrospective cohort of obese, GLP-1 receptor agonist (GLP-1 RA) initiators without recent major depressive disorder (MDD), we hypothesize that a rapid weight loss velocity (>1 kg/week) during the initial 90 days of treatment is associated with a higher hazard of incident MDD compared to gradual weight loss (<0.5 kg/week). We predict this association will be robust to extensive adjustment for confounding variables including baseline comorbidities, medications, and healthcare utilization patterns, and will be most pronounced in subgroups with pre-existing psychiatric vulnerability (e.g., anxiety disorders) and among female users.

Rationale: Current evidence on the psychiatric risks of GLP-1 RA is contradictory, likely due to significant indication and detection biases inherent in real-world data. Our hypothesis resolves this conflict by positing that the risk is not a direct pharmacological effect but is mediated by the physiological stress of rapid catabolism. This approach is supported by the need to meticulously control for a vast array of confounders identified in the literature—from metabolic and psychiatric comorbidities to medications—which existent studies may have inadequately addressed. By focusing on weight loss velocity, a currently uncharacterized patient response variable, we aim to isolate a specific, modifiable risk factor from the complex baseline characteristics of this population.

Proposed Experiment: Conduct a retrospective cohort study using electronic health records or claims databases (e.g., TriNetX, Optum, CPRD). Include

Hypothesis: Dasatinib+quercetin (D+Q) senolytic therapy preferentially eliminates senescent cells with high mitochondrial membrane potential heterogeneity, and the surviving non-senescent neighboring cells donate healthy mitochondria via tunneling nanotubes (TNTs) to partially reprogrammed cells in a 50-μm radius. This mitochondrial transfer resets local Horvath epigenetic clock age by 2–5 years in recipient cells within 8 weeks, mediated by mitochondrial-derived peptide MOTS-c activating AMPK-dependent TET2 demethylation at clock CpG sites.

Testable prediction: In human adipose tissue biopsies pre- and post-D+Q treatment (3 monthly cycles), single-cell DNA methylation sequencing will show bimodal epigenetic age distributions at week 12, with TNT-connected cell pairs (identified by MitoTracker Deep Red transfer) showing concordant clock regression (Δage correlation r>0.7, p<0.001) while isolated cells show no age reversal. MOTS-c knockdown via antisense oligonucleotides in ex vivo tissue explants should abolish this effect.

Significance: This mechanism would explain why senolytics produce tissue-level rejuvenation disproportionate to the fraction of senescent cells eliminated (<15% of total), and suggests MOTS-c supplementation could amplify senolytic efficacy by enhancing mitochondrial transfer-mediated epigenetic reprogramming in aging tissues.

Background: Rheumatoid arthritis (RA) synovium accumulates senescent p16^INK4a-high fibroblast-like synoviocytes (FLS) that exhibit a senescence-associated secretory phenotype (SASP) enriched in IL-6, MMPs, and CXCL1. These cells drive epigenetic clock acceleration (Horvath delta-age +5-12 years in synovial tissue vs. matched blood). Biologic DMARD non-response in RA correlates with senescent cell burden.

Hypothesis: Targeted senolytic therapy (dasatinib + quercetin or navitoclax) that reduces synovial p16^INK4a-high FLS burden by >=60% will reverse Horvath epigenetic clock acceleration in synovial tissue by >=3 years within 16 weeks AND restore clinical response to previously failed biologic DMARDs (TNFi or IL-6Ri) in >=50% of treatment-refractory RA patients.

Mechanism: Senescent FLS create a paracrine SASP microenvironment that (1) drives epigenetic reprogramming of neighboring stromal cells via IL-6/STAT3-mediated DNMT3A upregulation, (2) maintains pathogenic tissue-resident memory T cells through CXCL9/10 retention signals, and (3) generates a cytokine milieu that competes with biologic mechanisms of action. Senolytic clearance would dismantle this self-reinforcing circuit.

Testable predictions: (1) Pre/post synovial biopsy showing >=60% reduction in p16+/SA-beta-gal+ FLS after 4 weeks of senolytics; (2) Horvath clock reversal >=3 years in synovial (not blood) DNA methylation at week 16; (3) Re-challenge with previously failed biologic achieving ACR50 response in >=50% of subjects by week 28; (4) SASP factor panel (IL-6, MMP-3, CXCL1) reduction >=50%

We usually think of genomic aging as a simple loss of information, where our DNA "blueprints" just wear out over time. However, growing evidence suggests that vascular senescence might actually be driven by the reactivation of ancient genomic parasites—specifically transposable elements (TEs) like LINE-1. These repetitive sequences make up over 45% of the human genome, and while they’re typically kept under wraps by methylation and dense heterochromatin, that control slips as we age. My hypothesis is that vascular aging results from a failed cellular compromise: a shift from canonical to noncanonical STING signaling triggered by the chronic accumulation of TE-derived cytosolic DNA.

In young cells, the cGAS-STING pathway acts as a sharp viral sensor. Once it spots foreign DNA, cGAS generates cGAMP, which sets off STING phosphorylation and an IRF3-mediated interferon response [Frontiers in CV Med 2025]. But as epigenetic silencing fails in older cells, they're inundated with endogenous retrotransposon cDNA. I’d argue that the noncanonical STING signaling found in senescent cells—marked by lower cGAMP levels and dampened STING phosphorylation [PNAS 2024]—isn't just a glitch. It’s likely an adaptation I call "Signal Saturation Fatigue" (SSF). To keep from hitting the self-destruct button (apoptosis or pyroptosis) under the weight of this massive internal "viral load," the cell throttles its canonical cGAS-STING axis.

This survival tactic backfires, creating a "zombie state" with several consequences:

1. Persistent Sterile Inflammation: Noncanonical STING keeps driving NF-

Background

Rituximab retreatment in ANCA-associated vasculitis (AAV) remains empirically guided — fixed 6-month intervals or reactive retreatment upon relapse. Neither strategy is patient-specific. B-cell activating factor (BAFF/BLyS) rebounds predictably after B-cell depletion, but the shape of this rebound carries unexploited prognostic information.

Hypothesis

The log-linear slope of serum BAFF rebound between weeks 4–16 post-rituximab, analyzed via Bayesian online change-point detection (BOCPD), identifies a patient-specific inflection point that predicts the optimal retreatment window — defined as the latest point before immunological reconstitution reaches relapse-permissive thresholds. Patients retreated within 4 weeks of their BOCPD-identified inflection point will achieve >80% concordance with relapse-free survival at 12 months, compared to <60% under fixed-interval protocols.

Mechanistic Rationale

Post-depletion BAFF excess drives transitional B-cell maturation and, critically, survival of autoreactive clones that escaped deletion. The rebound follows a biphasic pattern: initial rapid rise (weeks 2–8) reflecting stromal BAFF release from reduced consumption, then a secondary inflection when reconstituting B-cells begin consuming BAFF. The timing of this second inflection varies 8–24 weeks across patients, governed by bone marrow regenerative capacity, residual tissue B-cells, and BAFF-R polymorphisms (rs7258002, rs9514828).

BOCPD with a conjugate Normal-Inverse-Gamma prior on BAFF log-concentrations can detect this regime shift in real-time from se

IF adults with prediabetes and mild executive-function deficits are randomized for 6 weeks to an intervention that specifically reduces post-prandial glucose variability (CGM-guided meal sequencing + 10-15 min post-meal walking + early eating window), while matched controls receive standard calorie advice only,\n\nTHEN the intervention arm will show larger improvements in executive function (Stroop interference, task-switch cost, N-back accuracy) and psychomotor vigilance than controls, even when between-group HbA1c change is small (<0.2%),\n\nBECAUSE glucose volatility (high MAGE/SD and repeated rapid excursions) is expected to drive transient endothelial stress and cytokine pulses (IL-6, TNF-alpha, hsCRP), which in turn perturb fronto-striatal network efficiency more directly than average glycemia.\n\n## Testable design\n- Population: age 40-65, prediabetes (HbA1c 5.7-6.4), no dementia\n- Duration: 6 weeks\n- Primary exposure: change in MAGE + time-above-range (CGM)\n- Primary outcomes: change in executive composite z-score\n- Secondary outcomes: IL-6, TNF-alpha, hsCRP, resting-state fronto-parietal connectivity\n\n## Falsification criteria\nThis hypothesis is weakened if:\n1. Executive function improves without any measurable reduction in glucose variability, or\n2. Variability decreases but cognitive performance and inflammatory markers do not improve versus control.\n\n## Why this matters\nIf confirmed, metabolic-cognitive prevention should target variability-first phenotypes (dynamic glycemic instability), not just static HbA1c thresholds.

The Telomere Mirage

We’ve spent decades treating the "Hayflick limit" and telomere attrition as the definitive molecular clock of aging. But this focus overlooks a major biological reality: post-mitotic cells like neurons and cardiomyocytes, which see almost no telomere shortening, still suffer from functional decline and epigenetic drift. I’m convinced telomere length is just a high-visibility readout of cumulative stress—a "cellular odometer" rather than the engine driving the process. The real driver of aging is likely the progressive failure of DNA repair pathway choice. Specifically, we're seeing a shift from high-fidelity Non-Homologous End Joining (NHEJ) toward mutagenic alternative pathways, fueled by a breakdown in nuclear compartmentalization.

Mechanistic Breakdown: The 53BP1/BRCA1 Tug-of-War

Genomic stability in the G1 phase hinges on the strict recruitment of 53BP1 to double-strand breaks (DSBs). This blocks end-resection and keeps canonical NHEJ on track. In older cells, this barrier fails. Evidence suggests that aged human cells struggle with 53BP1 recruitment because H4K20 methylation patterns change PMC7803562. This failure lets BRCA1/CtIP kick off ectopic end-resection in G1—a phase where homologous recombination (HR) can’t actually finish because there’s no sister chromatid template to use.

This "pathway leakage" pulls in error-prone alternative end-joining (alt-EJ) mechanisms, which drive the chromosomal translocations and deletions typical of the aged genome [Aging-US](https://www

Enterochromaffin (EC) cells face a metabolic trap no other gut epithelial cell encounters: their core function — serotonin biosynthesis via Tph1 — generates a reactive oxygen species (ROS) byproduct that may erode their own telomeres. This creates a feed-forward loop where 5-HT production intrinsically limits EC cell lifespan, independent of mitotic count.

The Core Mechanism

Serotonin auto-oxidation is well-documented. 5-HT readily oxidizes in the presence of molecular oxygen and transition metals, producing superoxide, hydrogen peroxide, and quinone intermediates that form protein and DNA adducts [PMC3564505]. EC cells package 5-HT into dense-core granules at high local concentrations — precisely the conditions that favor auto-oxidation. The resulting ROS, particularly H₂O₂, can diffuse across granule and nuclear membranes.

Telomeric DNA is disproportionately vulnerable. GGG repeats in TTAGGG sequences are oxidation hotspots; 8-oxo-guanine lesions at telomeres impair binding of shelterin proteins and trigger aberrant DNA damage responses even at modest damage levels [PMC3370421]. If EC cells sustain higher nuclear ROS than neighboring enterocytes — not from exogenous stress, but from endogenous 5-HT metabolism — their telomeres would erode faster per unit time, not per division.

The Model

This hypothesis proposes that EC cells operate under a unique oxidative constraint:

1. Synthesis burden: Continuous Tph1 activity and 5-HT packaging create a localized ROS microenvironment
2. Antioxidant saturation: EC cells possess baseline antioxidant defenses, but c

The current view positions eosinophils as a downstream convergence point that ameliorates multiple aging hallmarks when restored. But what if they are also part of a self-reinforcing regulatory loop whose failure creates the permissive environment for hallmarks to cascade? Here’s the synthesis: Eosinophils, via IL-4, don't just patch damage—they may actively maintain an epigenetic landscape conducive to repair and homeostasis in target tissues (liver, adipose, immune niches). Their age-related decline isn't just a loss of effector cells; it's a collapse of a maintenance signal that, in its absence, allows the epigenetic drift driving multiple hallmarks to accelerate.

Mechanistic proposal:

1. The Loop: Young, functional eosinophils are recruited to tissues in response to baseline damage. They secrete IL-4, which not only induces immediate anti-inflammatory and regenerative programs in macrophages and hepatocytes but also induces or stabilizes a specific set of chromatin modifiers (e.g., JMJD3, TET2) in these target cells. This promotes a gene expression profile that suppresses inflammation (lower IL-6/CCL2), supports mitochondrial function, and maintains stem cell quiescence.
2. The Upstream Trigger: The initiation of this loop depends on IL-5 and tissue-specific chemokine signals (e.g., CCL11). Critically, the responsiveness of this system may be governed by a yet-uncharacterized circadian or metabolic sensor in stromal or immune cells that senses systemic homeostatic pressure. This sensor's activity declines with age, leading to reduced I

Background

Randomized controlled trials in rare autoimmune diseases face chronic enrollment challenges, and treatment effect heterogeneity renders average estimates clinically insufficient. N-of-1 trials address individual response but lack rigorous counterfactual estimation — the fundamental question of what would have happened without intervention remains unanswered by simple pre-post comparison.

Hypothesis

We hypothesize that synthetic control methods (SCM), adapted from econometric causal inference, can construct patient-specific counterfactual disease trajectories using donor pools derived from longitudinal disease activity time series of untreated or alternatively-treated patients in registry data. Specifically:

1. For a patient initiating a biologic DMARD, a weighted convex combination of pre-treatment trajectories from k=15–50 donor patients (matched on baseline DAS28/SLEDAI trajectory shape, autoantibody profile, and CYP450 pharmacogenomic strata) will produce a synthetic counterfactual that satisfies pre-treatment fit criteria (RMSPE < 0.5 SD of the outcome variable).

2. The gap between observed post-treatment trajectory and synthetic control provides an individual causal treatment effect (ICTE) estimate, with permutation-based inference (placebo tests across donor pool) yielding valid p-values without distributional assumptions.

3. Augmented SCM (ASCM) incorporating ridge regression bias correction will reduce interpolation bias when the treated unit lies outside the convex hull of the donor pool, extending applicability to patients with aty